Clinical trials: Breast Cancer, Metastatic
Malignant Solid Tumour, Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an…
- Conditions
- Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST
- Trial name
- NCT01376505
- Testing
- HER-2 vaccine, Extension HER-2 vaccine trial at OBD
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Robert Wesolowski
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Metastatic Breast Cancer
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
To determine the safety of administering anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with metastatic breast cancer (MBC), as well as determining…
- Trial name
- NCT01802970
- Testing
- Anakinra plus Standard of Care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Breast Neoplasm
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.
- Trial name
- NCT01221870
- Testing
- Tesetaxel once every 3 weeks, Tesetaxel once weekly
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Genta Incorporated
Advanced Breast Cancer
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal…
- Trial name
- NCT00454805
- Testing
- AZD2171, Fulvestrant
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
The purpose of this study is to find the highest dose of durvalumab that can be tolerated without causing very severe side effects when receiving standard treatment and to see what effects the study drug has on this type of…
- Trial name
- NCT02649686
- Testing
- Durvalumab, Trastuzumab
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer Lymphedema
Comparison of Kinesiotaping and Pressure Garment on Women With Upper Extremity Lymphedema Following Mastectomy
Breast cancer is a standout amongst the most widely recognized cancer among women. It is observed that upper extremity lymphedema is one of the most dangerous and prevalent complication following breast cancer surgery which…
- Trial name
- NCT03401086
- Testing
- Kinesio Taping
- Where
- 2 sites in Egypt
- Volunteers
- 66 people
- Sponsor
- Ahlia University
Breast Cancer
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with…
- Trial name
- NCT07207070
- Testing
- JS105, Dalpiciclib, Fulvestrant 50 Mg/mL Intramuscular Solution
- Where
- 2 sites in China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
Breast Neoplasms
Project Connect Online: An Internet-based Intervention for Women With Breast Cancer
This randomized comparative effectiveness trial examines the potential psychosocial and physical health-related benefits of sharing personal websites with other women with breast cancer, as well as with family and friends (PCO…
- Trial name
- PCO (NCT02866994)
- Testing
- Project Connect Online, PCO PLUS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Stage IV Breast Cancer
Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Trial name
- NCT00003454
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Burzynski Research Institute
Breast Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
RATIONALE: Gathering information from patients of different ages receiving paclitaxel albumin-stabilized nanoparticle formulation for metastatic breast cancer may help doctors understand how the age of the patient changes the way…
- Trial name
- NCT00609791
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study, physiologic testing
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
HIV Infection, Recurrent Anal Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
This phase I clinical trial is studying the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and human…
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer
- Trial name
- NCT01249443
- Testing
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
Breast Cancer Stage IV
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy.
- Trial name
- SIMPHONY (NCT03324425)
- Testing
- Simvastatin 80mg
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Baylor Breast Care Center
Metastatic Triple-Negative Breast Cancer
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.
- Trial name
- NCT05089643
- Testing
- Anlotinib, Capecitabine
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer
This is a randomized, open-label, parallel, multi-center study, aims to evaluate the efficacy and safety of metronomic chemotherapy with oral Navelbine versus intermittent oral Navelbine in female patients with HER2 negative…
- Trial name
- NCT03854617
- Testing
- Oral NVB Metronomic, Oral NVB Weekly
- Volunteers
- 172 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
This is a multi-center, observational study designed to explore the regulatory mechanism of palbociclib correlative pathways in therapeutic process of breast cancer, employing next generation sequencing (NGS) on DNA and RNA.
- Trial name
- NCT04289974
- Testing
- Palbociclib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Breast Cancer
Lonafarnib in Metastatic Breast Cancer
A published phase 2 study reported that lonafarnib was administered as a single agent via continuous or intermittent oral dosing to 76 women with advanced breast cancer who were previously treated with chemotherapy and/or with…
- Trial name
- NCT00773474
- Testing
- Lonafarnib
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- George Sledge
Metastatic Breast Cancer
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.
- Trial name
- NCT01937507
- Testing
- HAI with FOLFOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Western Regional Medical Center
HR+/HER2- Breast Cancer, Metastatic Disease
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.
The ATLANT study is prospective, multicentre, non-interventional, observational study. Patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy.
- Conditions
- HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease
- Trial name
- ATLANT (NCT05789771)
- Testing
- Abemaciclib
- Where
- Russia
- Volunteers
- 136 people
- Sponsor
- Blokhin's Russian Cancer Research Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.